CDTX - Cidara Therapeutics, Inc.

QQQ $ 604.04 $ 3.94 (0.66 %)

DIA $ 461.73 $ 2.22 (0.48 %)

SPY $ 664.60 $ 3.75 (0.57 %)

TLT $ 91.13 $ -0.14 (-0.15 %)

GLD $ 390.85 $ -7.46 (-1.88 %)

Previous Close

$ 101.52

Open

$ 99.00

Bid

$ 100.00 x 3

Ask

$ 101.38 x 200

Day's Range

$ 98.45 - $ 103.02

52 Week Range

$ 10.37 - $ 121.21

Volume

765,546

Average Volume

Market Cap

2.57B

Beta (5Y Monthly)

$ 1.77

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2025	06-30-2025	10-Q
2	05-08-2025	03-31-2025	10-Q
3	03-06-2025	01-01-1970	10-K
4	11-07-2024	09-30-2024	10-Q
5	08-13-2024	06-30-2024	10-Q
6	05-15-2024	03-31-2024	10-Q
7	04-22-2024	12-31-2023	10-K
8	11-02-2023	09-30-2023	10-Q
9	08-03-2023	06-30-2023	10-Q
10	05-11-2023	03-31-2023	10-Q
11	03-23-2023	12-31-2022	10-K
12	11-03-2022	09-30-2022	10-Q
13	08-09-2022	06-30-2022	10-Q
14	05-11-2022	03-31-2022	10-Q
15	03-07-2022	12-31-2021	10-K
16	11-10-2021	09-30-2021	10-Q
17	08-12-2021	06-30-2021	10-Q
18	05-13-2021	03-31-2021	10-Q
19	02-25-2021	12-31-2020	10-K
20	11-05-2020	09-30-2020	10-Q
21	08-13-2020	06-30-2020	10-Q
22	05-13-2020	03-31-2020	10-Q
23	03-04-2020	12-31-2019	10-K
24	11-08-2019	09-30-2019	10-Q
25	08-08-2019	06-30-2019	10-Q
26	05-09-2019	03-31-2019	10-Q
27	02-28-2019	12-31-2018	10-K
28	11-08-2018	09-30-2018	10-Q
29	08-09-2018	06-30-2018	10-Q
30	05-10-2018	03-31-2018	10-Q
31	02-27-2018	12-31-2017	10-K
32	11-08-2017	09-30-2017	10-Q
33	08-09-2017	06-30-2017	10-Q
34	05-10-2017	03-31-2017	10-Q
35	03-15-2017	12-31-2016	10-K
36	11-10-2016	09-30-2016	10-Q
37	08-11-2016	06-30-2016	10-Q
38	05-12-2016	03-31-2016	10-Q
39	03-18-2016	12-31-2015	10-K
40	11-16-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Morgan Stanley Initiates Coverage On Cidar...
10/16/2025 13:07:28

Morgan Stanley analyst Maxwell Skor initiates coverage on Cidara Therapeutics (NASDAQ:CDTX) with a Overweight rating and ann...

cidara-therapeutics-analyst-says-lead-influenza-candidate-is-strategically-attractive

Cidara Therapeutics Analyst Says Lead Infl...
10/10/2025 18:11:11

JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's...

cidara-therapeutics-surges-ahead-of-eswi-2025-presentation-and-jp-morgan-coverage

Cidara Therapeutics Surges Ahead of ESWI 2...
10/10/2025 14:55:59

Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading higher on Friday after the biotech company made a recent announcement ...

Cidara Therapeutics To Present CD388 NAVIG...
10/10/2025 12:14:57

JP Morgan Initiates Coverage On Cidara The...
10/10/2025 11:32:13

JP Morgan analyst Anupam Rama initiates coverage on Cidara Therapeutics (NASDAQ:CDTX) with a Overweight rating and announces...

WBB Securities Maintains Strong Buy on Cid...
10/09/2025 18:33:40

WBB Securities analyst Steve Brozak maintains Cidara Therapeutics (NASDAQ:CDTX) with a Strong Buy and raises the price targe...

HC Wainwright & Co. Maintains Buy on Cidar...
10/09/2025 14:50:58

HC Wainwright & Co. analyst Sara Nik maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and raises the price target ...

FDA Grants Breakthrough Therapy Designatio...
10/09/2025 12:02:37

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...

cidara-shares-are-trading-higher-friday-whats-going-on

Cidara Shares Are Trading Higher Friday: W...
10/03/2025 16:53:54

Cidara shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic i...

JMP Securities Maintains Market Outperform...
10/03/2025 12:07:49

JMP Securities analyst Roy Buchanan maintains Cidara Therapeutics (NASDAQ:CDTX) with a Market Outperform and raises the pric...

Cidara Secures Up To $339M BARDA Award To ...
10/02/2025 20:06:30

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...

HC Wainwright & Co. Maintains Buy on Cidar...
09/26/2025 10:44:24

HC Wainwright & Co. analyst Sara Nik maintains Cidara Therapeutics (NASDAQ: CDTX) with a Buy and raises the price target...

Cidara Therapeutics Announces First Partic...
09/25/2025 20:03:26

- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere- Participants will include adults ove...

Guggenheim Maintains Buy on Cidara Therape...
09/25/2025 12:56:16

Guggenheim analyst Seamus Fernandez maintains Cidara Therapeutics (NASDAQ: CDTX) with a Buy and raises the price target from...

Needham Maintains Buy on Cidara Therapeuti...
09/24/2025 16:10:22

Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and raises the price target from $74 ...

WBB Securities Reiterates Strong Buy on Ci...
09/24/2025 11:22:28

WBB Securities analyst Steve Brozak reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Strong Buy and maintains $123 price ...

Cidara Therapeutics Announced Updates To I...
09/24/2025 11:09:04

Cidara is proceeding with an expanded and accelerated development plan seeking biologics license application (BLA) approval bas...

WBB Securities Maintains Strong Buy on Cid...
09/22/2025 12:13:12

WBB Securities analyst Steve Brozak maintains Cidara Therapeutics (NASDAQ:CDTX) with a Strong Buy and raises the price targe...

Cidara Therapeutics Presents Data On CD388...
09/17/2025 12:05:06

- Efficacy and safety results from successful NAVIGATE Phase 2b trial of CD388 for prevention of influenza illness featured in ...

Cidara Therapeutics To Present Two Oral Se...
09/03/2025 12:06:58

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...